PremiumCompany AnnouncementsCV Sciences Reports 2024 Financial Results and Growth Plans CV Sciences reports FY24 EPS (1c) vs. (2c) last year CV Sciences Disputes Stock Purchase Agreement Termination PremiumThe FlyRising High: Innovative Industrial reports PharmaCann default Rising High: Exclusive talk with biopharma company HMNC Brain Health Rising High: Organigram acquires Motif Labs for C$90M upfront PremiumThe FlyRising High: Cannabis firms report quarterly earnings CV Sciences Reports Q3 Revenue and Product Launch Rising High: Exclusive talk with house of brands Carma HoldCo